Evidence map›Paper›PMID 34913098›Full record

ArticleEuropean journal of hybrid imaging2021

Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis.

Edward Cheung, Sarah Ahmad, Matthew Aitken, Rosanna Chan, Robert M Iwanochko, Meyer Balter, Ur Metser, Patrick Veit-Haibach, Filio Billia, Yasbanoo Moayedi and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of hybrid imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03356756 (Diagnostic and Prognostic Significance of Combined PET/MRI in Inflammatory Cardiomyopathies and Sarcoidosis), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03356756 completednot on this map

Diagnostic and Prognostic Significance of Combined PET/MRI in Inflammatory Cardiomyopathies and Sarcoidosis

TypeobservationalSponsorUniversity Health Network, TorontoRan2016 to 2024Enrolled40ConditionsInflammatory Cardiomyopathy, SarcoidosisArmssimultaneous combined 18F-FDG PET and cardiac MRI imaging
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Diagnostic and prognostic value of T2 mapping in cardiac sarcoidosis.International journal of cardiology. Heart & vasculature · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Recent Progress of Cardiac MRI for Nuclear Medicine Professionals.Nuclear medicine and molecular imaging · 2024
    Review
  11. Review
  12. Exploring the latest advances inAmerican journal of nuclear medicine and molecular imaging · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Myocarditis Following COVID-19 Vaccination.Heart failure clinics · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Edward CheungDepartment of Medical Imaging, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, 585 University Avenue, 1 PMB-298, Toronto, ON, M5G 2N2, Canada.
Sarah AhmadDivision of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, 585 University Ave, Toronto, ON, M5G 2N2, Canada.
Matthew AitkenDepartment of Medical Imaging, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, 585 University Avenue, 1 PMB-298, Toronto, ON, M5G 2N2, Canada.
Rosanna ChanDepartment of Medical Imaging, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, 585 University Avenue, 1 PMB-298, Toronto, ON, M5G 2N2, Canada.
Robert M IwanochkoDivision of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, 585 University Ave, Toronto, ON, M5G 2N2, Canada.
Meyer BalterDivision of Respiratory Medicine, Sinai Health System, University of Toronto, 600 University Ave, Toronto, ON, M5G 1X5, Canada.
Ur MetserDivision of Molecular Imaging, Department of Medical Imaging, University Health Network, University of Toronto, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Patrick Veit-HaibachDivision of Molecular Imaging, Department of Medical Imaging, University Health Network, University of Toronto, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Filio BilliaDivision of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, 585 University Ave, Toronto, ON, M5G 2N2, Canada.
Yasbanoo MoayediDivision of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, 585 University Ave, Toronto, ON, M5G 2N2, Canada.
Heather J RossDivision of Cardiology, Peter Munk Cardiac Centre, University Health Network, University of Toronto, 585 University Ave, Toronto, ON, M5G 2N2, Canada.
Kate HannemanDepartment of Medical Imaging, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, 585 University Avenue, 1 PMB-298, Toronto, ON, M5G 2N2, Canada. kate.hanneman@uhn.ca.ORCID http://orcid.org/0000-0002-3077-2218
University Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the diagnostic and prognostic significance of combined cardiac

methodsPatients with suspected cardiac sarcoidosis were prospectively enrolled for cardiac

resultsForty-two patients (53 ± 13 years, 67% male) were evaluated, 13 (31%) with a final diagnosis of cardiac sarcoidosis. Among patients with cardiac sarcoidosis, 100% of patients had at least one abnormality on PET/MRI: FDG uptake in 69%, LGE in 100%, elevated T1 and ECV in 100%, and elevated T2 in 46%. FDG uptake co-localized with LGE in 69% of patients with cardiac sarcoidosis compared to 24% of those without, p = 0.014. Diagnostic specificity for cardiac sarcoidosis was highest for FDG uptake (69%), elevated T2 (79%), and FDG uptake co-localizing with LGE (76%). Diagnostic sensitivity was highest for LGE, elevated T1 and ECV (100%). After median follow-up duration of 634 days, 13 patients experienced MACE. All patients who experienced MACE had LGE, elevated T1 and elevated ECV. FDG uptake (HR 14.7, p = 0.002), elevated T2 (HR 9.0, p = 0.002) and native T1 (HR 1.1 per 10 ms increase, p = 0.044) were significant predictors of MACE even after adjusting for left ventricular ejection fraction and immune suppression treatment. The presence of FDG uptake co-localizing with LGE had the highest diagnostic performance overall (AUC 0.73) and was the best predictor of MACE based on model goodness of fit (HR 14.9, p = 0.001).

conclusionsCombined cardiac FDG-PET/MRI with T1/T2 mapping provides complementary diagnostic information and predicts MACE in patients with suspected cardiac sarcoidosis.

Indexed as

Cardiac MRICardiac sarcoidosisCMRFDG PETPET/MRISarcoidosis

Identifiers

PMID34913098
PMCPMC8674394
OpenAlexW4200198310

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.